Tobias Zutz, founder and CEO of Gregor Diagnostics in Madison, will receive $900,000 from investors, according to a Wisconsin State Journalstory, to develop an at-home screening test for prostate cancer that would test semen samples for biomarkers rather than blood.
The investment will pave the way toward the company’s first patient study. If all goes well, Zutz hopes the product could go to market in four or five years.
